Sleeping Beauty (SB 3 ) transposon and transposase constitute a DNA plasmid system used for therapeutic human cell genetic engineering. Here we report a comparison of SB100X, a newly developed hyperactive SB transposase, to a previous generation SB11 transposase to achieve stable expression of a CD19-specific chimeric antigen receptor (CAR 3 ) in primary human T cells. The electro-transfer of SB100X expressed from a DNA plasmid or as an introduced mRNA species had superior transposase activity in T cells based on the measurement of excision circles released after transposition and emergence of CAR expression on T cells selectively propagated upon CD19 + artificial antigen-presenting cells. Given that T cells modified with SB100X and SB11 integrate on average one copy of the CAR transposon in each T-cell genome, the improved transposition mediated by SB100X apparently leads to an augmented founder effect of electroporated T cells with durable integration of CAR. In aggregate, SB100X improves SB transposition in primary human T cells and can be titrated with an SB transposon plasmid to improve the generation of CD19-specific CAR + T cells.
INTRODUCTION
To overcome immune tolerance, T cells can be genetically modified to express chimeric antigen receptors (CARs) to redirect specificity to tumor-associated antigens, such as CD19 (ref. 1) . These transgenes can be introduced into T cells ex vivo using virus-based vectors and nonviral systems. Viral-based vectors are widely used in research and clinical trials as they provide stable transduction of target cells. 2, 3 However, retroviruses' non-random patterns of integration, at least in hematopoietic stem cells, could potentially activate/inactivate oncogenes/ tumor suppressor genes leading to deleterious autonomous T-cell proliferation. 4 Non-viral gene transfer systems based on transposable elements are an alternative approach to transduction to introduce desired transgenes into the genome. 5, 6 The Sleeping Beauty (SB) transposon system, which integrates at TA dinucleotides apparently randomly across the genome, can be adapted for genetic engineering of T cells. [7] [8] [9] This is a result of the stable and efficient integration of an electro-transferred SB transposon by the enzymatic activity of an SB transposase, which is typically introduced as a separate DNA plasmid in trans from the DNA plasmid expressing the transposon. SB11 is a hyperactive SB transposase reported to achieve about 100-fold higher integration rates than those achieved by DNA plasmids without transposase activity that use illegitimate recombination to achieve integration. 10 On the basis of the SB11 transposase, we are undertaking gene therapy clinical trials (INDs no. 14193 and no. 14577) infusing CD19-specific T cells that have been electroporated to introduce SB transposon and transposase to generate CAR + T cells, which can be selectively propagated on CD19 + artificial antigenpresenting cells (aAPC 3 ). 11, 12 Using this approach, clinically sufficient numbers of T cells can be obtained within a few weeks after electroporation of the SB DNA plasmids.
Improvements to the efficiency of transposition may augment our ability to generate CAR + T cells. Therefore, we investigated the integration efficiency of a CD19-specific CAR transposon, designated CD19RCD28, using a new mutant of SB transposase termed SB100X, 13 which had been systematically engineered to have increased enzymatic activity in mammalian cells. Follow-up studies have validated the superiority of SB100X transposase activity in mouse embryonic stem cells and human hematopoietic stem cells. 5, 14 In preparation for a next-generation trial using the SB system, we compare for the first time the ability of SB11 and SB100X to generate CAR + T cells from human peripheral blood mononuclear cells (PBMC). Our data reveal that SB100X results in 10 to 100 times more transposition events than SB11, as determined by the excision of transposon from DNA plasmid, which resulted in three to four times more efficient outgrowth of CD19-specific CAR + T cells within 28 days after electroporation, and with approximately one copy of CAR transposon per T-cell genome. This apparent increase in enzymatic activity of SB100X is highlighted by our ability to achieve superior outgrowth of CAR + T cells using just one-tenth the amount of DNA plasmid coding for SB100X compared with SB11.
RESULTS

Measuring SB transposition by quantifying excision circles
It has been reported that SB100X results in improved transposition in mouse and human cells. 14, 18 Therefore, we determined the relative ability of SB100X versus SB11 to mediate a transposition event by quantitative-polymerase chain reaction (Q-PCR) adapted to measure DNA fragments (excision circle) 19 that are the expected by-product produced when CAR transgene (transposon) integrates into the T-cell genome, as schematically shown in Figure 1a . The DNA plasmids used to introduce SB transposase in this study are shown in Figures 1b and c.
SB100X transposase improves frequency of transposition
To assess directly the ability of SB100X to improve the frequency of transposition compared with SB11 transposase, we serially measured the formation of non-integrated excision circles (products) by realtime Q-PCR after electroporation of T cells from PBMC. The transient accumulation of excision circles represents the enzymatic activities of the two SB transposases, whereas measurement of the electro-transferred SB transposon and subsequent expression of CD19RCD28 CAR indicates the overall integration efficiency of the non-viral gene transfer process. To account for variations in electro-transfer efficiency, we normalized the excision circle data to the amount of DNA transposon recovered after electroporation (excision circle to CD19RCD28 ratio). This revealed the individual SB transposase's enzymatic activities and adjusted for possible difference in electroporation efficacy between different samples. Measurement of RPPH1, a subunit of RNase P, 20 which is present at one copy on chromosome 14q11.2, was used as internal control in real-time Q-PCR for both quantification of excision circles and transposon DNA species. By varying the relative amounts of DNA plasmids coding for the transposases, SB100X reached peak activity at a concentration of 5 mg per electroporation (Figure 2b) . However, at 10 mg per electroporation, SB100X resulted in significant loss of PBMC viability (data not shown). This decrease in excision products when 10 mg of SB100X DNA plasmid was used per electroporation could be due to DNA toxicity, although this was not observed with SB11, but is more likely due to over-production inhibition. SB11 also showed maximal activity at 5 mg per electroporation (Figure 2a ), but the amount of excision circles produced was significantly less than that achieved with SB100X. Figure 1 Schematic showing the formation of excision circles and integration of transgene using DNA plasmids from SB system. (a) The transgene (transposon) to be integrated is flanked by two IR and mobilized from the CD19RCD28mZ(CoOp)/pSBSO plasmid by SB transposase. Upon SB transposition, the CAR transposon (CD19RCD28) is inserted into the T-cell genome, whereas the non-integrated DNA forms an episomal excision circle. The PCR to detect a released excision circle reveals a 77 base pair band, whereas the same primers bound to sites in the CD19RCD28mZ(CoOp)/pSBSO plasmid are 4298 base pairs apart. (b) Schematic of DNA plasmids expressing SB11 transposase and (c) SB100X transposase. BGH, bovine growth hormone polyadenylation signal sequence; CDS, coding sequence of gene; CMV/p, cytomegalovirus promoter; ColE1, colicin E1 (origin of replication); hEF-1a/p, human elongation factor-1a hybrid promoter; IR, inverted repeats; Kan/R, kanamycin resistance gene; Kan/P, kanamycin resistance gene promoter; SV40 poly A, Simian virus 40 polyadenylation signal sequence.
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Overall, SB100X was apparently 10 to 100 times more active compared with SB11. As expected, the episomal excision circles are lost to detection as the T cells propagate on the aAPC. To avoid the possibility that the SB transposases could integrate, we assessed whether improved transposition could also be achieved by mRNA coding for SB100X. The two transposases were electro-transferred as mRNA species along with a fixed amount of SB DNA transposon into T cells pre-activated by crosslinking CD3 with the monoclonal antibody OKT3. We observed that the introduction of SB100X mRNA at 0.1 mg per electroporation was as active as 10Â the amount of SB11. When SB100X mRNA was used at 0.25 mg per electroporation, there was a higher transposition activity compared with SB11 at 1 mg per electroporation (Figure 2c ). These data indicate the superior activity of SB100X in primary T cells whether this transposase is expressed from electro-transferred DNA or mRNA. CAR + T cells can be generated using SB100X mRNA As SB transposase coded by mRNA species was capable of accomplishing SB transposition, we determined if CAR + T cells could be selectively propagated on aAPC after electro-transfer of DNA plasmid coding for CD19RCD28 and mRNA coding for SB100X or SB11. We adapted our propagation method to generate CAR + T cells (Figure 4a ), so that T cells were pre-activated with OKT3 to improve uptake of and expression from mRNA. As shown in Figure 4b , 0.25 mg per electroporation of SB100X and 1 mg per electroporation of SB11 successfully produced CAR + T cells that could be propagated on CD19 + aAPC. The superiority of the SB100X transposase to support the outgrowth of CAR + T cells was apparently not due to differences in integrity of the mRNA (Figure 4c ). 
Generation of CAR + T cells by SB transposition
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Transposition using SB100X and SB11 result in comparable number of integration events per T cell Given that SB100X gives rise to a greater number of transposition events compared with SB11, we investigated whether this enzyme resulted in multiple integration events. To evaluate the number of integration events per electroporated and propagated T cell, we measured the copy number of CD19RCD28 transpose relative to the copy number of RNase P gene by real-time Q-PCR. The calculated transgene copy per T cell is 0.95±0.068 gene (mean±s.e.m.) for 0.5 mg per electroporation SB100X and 0.80 ± 0.033 (mean ± s.e.m.) for 5 mg per electroporation SB11, respectively (Figure 5a ). This difference is not statistically significant (P¼0.185) when measured at a time point when sufficient (clinical grade) CAR + T cells are available that can be harvested from cultures for adoptive immunotherapy. These data revealed that the number of integrated copies of CAR is approximately 1 per T-cell genome upon transposition with both SB100X and SB11.
SB100X DNA cannot be detected in electroporated and propagated T cells To establish that SB100X or SB11 DNA is not present in propagated T cells, we developed a Q-PCR assay to reveal integrated transposase plasmid. Our data show that after 28 days of in vitro culture, the SB100X transposase, as well as that of SB11, are absent in the cultured cells (Figure 5b ). The standard curves associated with this assay are in the Supplementary Data.
CAR + T cells generated by SB transposition with SB100X exhibit redirected killing for CD19 + tumor cells We have previously shown that CAR + T cells genetically modified with SB11 transposase specifically lyse B-cell tumor cells. 8 The electroporated and propagated T cells generated using SB100X transposase (using 0.1 mg per electroporation) were evaluated for their ability to be activated for effector functioning in a CAR-dependent manner. We showed by chromium release assay that CAR + T cells exhibited redirected specific lysis of a genetically modified EL4 target expressing 92% human CD19 (Figure 6a ). T cells not genetically modified, but propagated by crosslinking CD3 using g-irradiated aAPC loaded with OKT3 did not appreciably lyse CD19 À EL4 cells (Figure 6b ).
DISCUSSION
We and others have used transposon and transposase systems to improve integration efficiency of DNA plasmids expressing immunoreceptors. 8, 9, 17, 21, 22 Building upon these data, we have adapted the SB system for human application 11 to use the SB11 transposase to integrate CAR into TA dinucleotide repeats across the genome of populations of human T cells. The development of SB100X raised the possibility that we could use this new SB transposase to improve the integration frequency of CAR transposon in T cells. We were able to show that SB100X had up to 100 times higher rates of transposition compared with SB11 based on the release of excision circles. This is attributed to improved enzymatic activity, but the improved transposition efficiency may also be due to different translational efficiencies as well as post-translational modifications. The efficiency of transposition was dependent on the amount of electro-transferred transposase, but an elevated input concentration of SB100X led to cell death. The reasons for this toxicity are not known, however, it is apparent that overexpression of transposase can lead to inhibition of SB transposition. 6, 16 This highlights the need to titrate the input DNA plasmid concentrations between the transposon and the transposase. By reducing the amount of SB100X relative to SB11, we were able to show its superior activity. 
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The ability of SB100X to augment the selective propagation of CAR + T cells on CD19 + aAPC raised the possibility that this transposase led to the insertion of multiple copies of the transposon per cell. Indeed, multiple integrations have been observed after SB100X-mediated transposition in other cells. 6, 13 However, this was disproved when we found that on average, there was approximately one copy of the CAR transgene per T cell, which was similar to the integration efficiency associated with SB11. Our lower number of integrants per genome compared with the published reports of SB100X activity may be due to an intrinsic property of the T-cell genome, genotoxicity leading to loss of viability of T cells carrying multiple copies of the transposon, a reduced amount of SB100X DNA plasmid electro-transferred, and/or a reflection of the selective pressure provided by the aAPC to selectively propagate CAR + T cells bearing just one copy of the transposon.
That SB100X has intrinsically improved transposase activity is revealed by the release and detection of more excision circles when SB100X was used compared with SB11. Presumably, the release of the excision circles from a population of electroporated T cells is correlated with the stable integration of the CAR transgene, which is measured per T cell. Thus, it appears that the superior enzymatic activity of SB100X results in an improved efficiency of transposon integration and a beneficial founder effect leading to the subsequent improved outgrowth of CAR + T cells upon in vitro propagation on aAPC. This finding pertains to the safety of SB100X for, as with SB11, it does not lead to multiple insertions of the CAR transgene when T cells are electroporated and co-cultured on aAPC.
The increased enzymatic activity of SB100X was also evident when we reduced the amount of transposase DNA plasmid needed to accomplish the integration of CAR into T cells. Indeed, we could achieve superior numeric expansion of CAR + T cells on CD19 + aAPC using 0.5 mg per electroporation of SB100X compared with 10 times as much DNA plasmid coding for SB11. This also has implications for improved safety of SB system in human trials as a decrease in the amount of SB transposase delivered by DNA plasmid presumably decreases the chance of inadvertent integration of the transposase into the genome and the potential for re-mobilization of the inserted transposon. When we evaluated for the presence of integrated plasmid expressing SB100X, we did not detect a signal by Q-PCR, which curtails the possibility of a re-hopping event after SB-mediated transposition. However, it is possible that DNA for SB transposase was present in the genome at a level below the limit of detection by (a) Copy number of CAR transgene, normalized to RNase P, at day 28 of co-culture on CD19 + aAPC after SB transposition with SB100X or SB11. Q-PCR using CAR-specific primers revealed CD19RCD28 copy numbers at 0.95 and 0.80 transgene per T-cell genome after electro-transfer of 0.5 mg DNA plasmid coding for SB100X, and 5 mg DNA plasmid coding for SB11, respectively. There was no statistical difference between the copy number of integrated CAR transgenes. (b) Measurement by Q-PCR using transposase-specific primers at day 1 (day after electroporation) and at day 28 of co-culture of genetically modified T cells on CD19 + aAPC. Transposon was added at 15 mg per electroporation along with graded doses of DNA plasmids coding for SB100X and SB11 transposases.
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To exclude the possibility that SB100X can integrate into the T-cell genome, we showed that electro-transfer of mRNA species coding for this integrase could mediate transposition, and further that the efficiency of integration was again higher than SB11. Previously, it has been shown that SB11 transposase coding by mRNA can mediate transposition. 23 Furthermore, viral vectors have been used to deliver SB transposase to improve the pattern of integration of an integrase-deficient lentivirus to achieve a more random pattern of integration than can be achieved with lentiviral integrase. 24, 25 We are currently undertaking the first clinical applications of the SB system, which has successfully received Investigational New Drug Applications from the Food and Drug Administration, to electrotransfer the SB11 transposase to express CD19RCD28 transposon in autologous and allogeneic T cells for infusion in patients with B-lineage lymphoma. With the development of SB100X, our data show that this transposase may be a desirable alternative transposase to the use of SB11 for use in future clinical trials to adoptively transfer CAR + T cells.
MATERIALS AND METHODS Plasmids
The SB transposon contains the CoOp second-generation CD19RCD28 CAR, specific for human CD19, flanked by the SB inverted repeats. This CAR has been described previously. 15 In brief, the ampicillin resistance gene (AmpR) and origin of replication from the plasmid CoOpCD19RCD28/pT-MNDU3 was replaced with a DNA fragment encoding the kanamycin resistance gene (KanR) and origin of replication (ColE1) from the pEK Vector. 8 The human elongation factor-1a promoter from pVitro4 vector (InvivoGen, San Diego, CA, USA) was swapped with MNDU3 promoter to generate the DAN plasmid CD19RCD28mZ(CoOp)/pSBSO (Figure 1a) . The pKan-CMV-SB11 DNA plasmid (Figure 1b) , coding for the SB11 transposase, was constructed by digesting pCMV-SB11 (kindly provided by Dr Perry Hackett, University of Minnesota, Minneapolis, MN, USA) 16 with PvuII, harvesting the fragment coding for SB11 transposase and ligating to the AseI and PacI fragment, which contained the KanR and ColE1 origin of replication from pEK vector. pKan-CMV-SB100X (Figure 1c) , coding for SB100X transposase, was built by digesting both the pKan-CMV-SB11 plasmid and pCMV(CAT)T7-SB100X plasmid 13 with AvaI and PsiI, and then annealing the fragment coding for SB100X with the backbone of pKan-CMV-SB11 plasmid. All DNA plasmids were purified using Qiagen (Valencia, CA, USA) endotoxin-free reagents. The integrity of the DNA plasmids coding SB100X and SB11 transposase was assessed by Experion automatic electrophoresis station (Bio-Rad, Hercules, CA, USA).
Cells
After obtaining consent, PBMC from healthy donors were isolated by density gradient centrifugation over Ficoll-Paque-Plus (Pharmacia Biotech, Piscataway, NJ, USA) and stored in liquid nitrogen. K562 were transduced with lentivirus to express CD64, CD86, CD137L and membrane-bound IL-15 and were cloned (clone no. 4, kindly provided by Dr Carl June, University of Pennsylvania, Philadelphia, PA, USA). The construction of CD19 + K562 aAPC was reported previously. 17 The parental murine immortalized EL4 T-cell line (catalog no. TIB-39; ATCC, Manassas, VA, USA) and human CD19 + EL4 transfectants were cultured in RPMI 1640 medium (Hyclone, Logan, UT, USA), supplemented with 2 mM Glutamax-1 (Gibco-Invitrogen, Carlsbad, CA, USA) and 10% heatinactivated fetal calf serum (FCS).
Generation of CAR + T cells by transposition with SB DNA plasmids coding for CAR and transposases
On day 0, PBMCs were thawed at 37 1C, washed once with phenol-free RPMI 1640 and rested for 2 h at 37 1C. A total of 2Â10 7 PBMC/cuvette were resuspended in Human T Cell Nucleofector buffer (Lonza Inc., Basel, Switzerland) along with 15 mg CD19RCD28mZ(CoOp)/pSBSO plasmid coding for CD19RCD28 CAR and graded doses of DNA plasmids coding for SB100X or SB11. After electroporation with Nucleofector II (Lonza Inc.) using program U14, the cells were washed once with phenol-free RPMI 1640 and resuspended in 1 ml of phenol-free RPMI 1640 (without FCS) and cultured in a 12-well plate at 37 1C for 4 h. Then, 1 ml of phenol-free RPMI 1640 with 20% of FCS was added. The next day, 3Â10 5 cells were harvested for DNA extraction and immunophenotyping. The remaining cells were stimulated by 1:2 (CAR + T cells:aAPC) weekly additions of g-irradiated (100 Gy) CD19 + aAPC (clone no. 4) for 28 days of continuous co-culture in RPMI 1640 supplemented with 2 mM Glutamax-1 and 10% heat-inactivated FCS. Recombinant human interleukin 2 (50 IU ml À1 ; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA) was added every other day beginning at day 1.
In vitro transcription to generate mRNA coding for SB100X and SB11
Twenty micrograms of the SB transposase plasmids were digested with SpeI and purified with Qiaquick gel extraction kit (Qiagen) and the DNA concentration was measured. Ten micrograms of the linearized plasmid DNA was used to synthesize mRNA with T7 RiboMAX Express Large Scale RNA Production System (Promega, Madison, WI, USA). A PolyA tail was added to the newly synthesized mRNA molecule with Poly(A) Tailing Kit (Ambion, Austin, TX, USA). After quantification, the mRNA was analyzed by gel electrophoresis, aliquoted and stored in Nalgene cryogenic vials (Thermo Fisher Scientific, Waltham, MA, USA) at À80 1C for future use.
Generation of CAR + T cells by transposition with SB DNA plasmid coding CAR and mRNA coding for transposases PBMC were resuspended in RPMI 1640 with 5% heat-inactivated AB human serum (Invitrogen) along with 50 ng ml À1 of OKT3 monoclonal antibody (eBioscience, San Diego, CA, USA) and 50 U ml À1 of IL-2, which was re-added to the culture every other day. After 5 days, 10 7 cells per cuvette were electroporated using 10 mg DNA plasmid (CD19RCD28mZ(CoOp)/pSBSO) coding for CD19RCD28 and graded amounts of SB transposase mRNA. The propagation of the T cells was achieved using 1:10 (CAR + T cells to aAPC) ratio of g-irradiated CD19 + aAPC for first 2 weeks and 1:2 ratio thereafter. aAPC clone no. 4 were added every 7 days and IL-2 every other day beginning at day 1.
Flow cytometry
Cells were first incubated with 1:200 diluted APC-labeled goat anti-human immunoglobulin G Fc (category (cat.) no. 12-0569-42; Jackson ImmunoResearch Laboratories Inc., West Grove, PA, USA), then washed once, and finally incubated with 1:50 anti-CD3-FITC (cat. no. 349201; BD Biosciences, Los Angeles, CA, USA) and 1:50 anti-CD56-PE (cat. no. 12-0569; eBiosciences). After staining, all cells were resuspended in 100 ml fluorescence-activated cell Sorting buffer (2% FCS and 0.1% sodium azide in phosphate-buffered saline) and live/dead cells were differentiated upon the addition of propidium iodide (catalog no. P4864; Sigma-Aldrich, St Louis, MO, USA), and then analyzed with flow cytometry (FACSCalibur; BD Biosciences).
Real-time Q-PCR
All of the primers, probes and TaqMan Gene Expression Master Mix were purchased from Applied Biosystem (Foster City, CA, USA). The Q-PCR reactions were performed in a Steponeplus Real-time PCR system (Applied Biosystem) with TaqMan real-time Q-PCR technique as recommended. To measure excision circles, the forward primer (5¢-TCCCAGTCACGACGTTG TAAAA-3¢) and probe (5¢-CCAGTGAATTCGAGCTC-3¢) bound 5¢ of the CAR cassette and the reverse primer (5¢-CGTTGGCCGATTCATTATCG-3¢) bound 3¢ of the CAR cassette in the SB transposon DNA plasmid CD19RCD28mZ (CoOp)/pSBSO as illustrated in Figure 1a . A positive PCR reaction reveals a 77 base pair band that is generated only after the CAR transposon was excised. To measure CD19RCD28 CAR, the primer sequences are as follows: forward primer, 5¢-CAGCGACGGCAGCTTCTT-3¢; reverse primer, 5¢-TGCATCACG-GAGCTAAA-3¢; and probe, 5¢-AGAGCCGGTGGCAGG-3¢. To measure SB transposases, a common primer and probe set were designed to target the plasmid backbone shared by pKan-CMV-SB100X and pKan-CMV-SB11. These sequences are as follows: forward primer, 5¢-AAGGCCAGGAACCGTAAAAAG-3¢; reverse primer, 5¢-GGCGGAGCCTATGGAAAAA-3¢; and probe, 5¢-CCGCGT TGCTGGC-3¢. RNase P primer and probe set of TaqMan RNase P Control Reagents Kit (cat. no. 4316844; Applied Biosystem) were used as Q-PCR internal control.
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Analysis of Q-PCR results
An RNase P C T versus cell number standard curve (Curve A, Supplementary  Figure 1s 1a ) was achieved by a serial dilution (200, 20 and 2 ng) of genomic DNA from a genetically modified Jurkat T-cell clone bearing one copy of CAR transgene based on Southern blotting (Maiti et al., in preparation). As one cell has about 7 pg of DNA, 200 ng total DNA is equivalent to approximately 28 570 cells. C T represents the threshold circle where the Q-PCR was deemed positive. With Curve A, we calculated the cell number from corresponding RNase P C T value. In parallel, a CD19RCD28 transgene C T versus transgene number curve (Curve B, Supplementary Figure 1s 1b ) was generated to compute the number of integrated transgenes. Twenty nanograms of sample genomic DNA from genetically modified and propagated primary T cells could then be analyzed by Q-PCR. The RNase P C T was used to calculate cell numbers with Curve A and the integrated transgene copy number was deduced from transgene C T with Curve B. The copy numbers per cell were calculated with the following formula:
Copy number per cell ¼ Tg N Cell N Tg N is the number of integrated transgenes and Cell N represents the cell number deduced from RNase P C T . Quantification of excision circle was achieved with comparative C T method provided by the Steponeplus real-time PCR system (Applied Biosystem).
Chromium release assay
The redirected specificity of the genetically modified T cells was determined by chromium release assay using 51 Cr-labeled EL4 cells as targets. The T cells (effectors) were harvested 28 days following stimulation with aAPC, washed and plated in V-bottom microtiter plates (Costar, Cambridge, MA, USA) in triplicate at 10 5 , 5Â10 4 , 2.5Â10 4 , 1.25Â10 4 cells per well and with 5Â10 3 target cells. After incubation at 37 1C for 4 h followed by centrifugation, 50 ml aliquots of cell-free supernatant were harvested and counted with Topcount NXT (PerkinElmer, Waltham, MA, USA). The percent of specific cytolysis was calculated from the release of 51 Cr as follows: 
Statistical analysis
The Student's t-test was employed to determine statistical significance and Po0.05 was considered significant. Where applicable, the data are reported as an average and s.d. Electroporations were performed on two different donors while Q-PCR reactions were carried out in triplicate.
